CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.64
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.23

24 Mar
2025

-0.195

OPEN

$1.38

-13.68%

HIGH

$1.38

388,443

LOW

$1.19

TARGET
$2.70 119.5% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 12.8 0.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 205.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-12.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.6 M
Book Value Per Share xxxxxxxxxxxxxxx38.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-12.6 M
Net Profit Margin xxxxxxxxxxxxxxx-47.87 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-35.20 %
Return on Invested Capital xxxxxxxxxxxxxxx-30.46 %
Return on Assets xxxxxxxxxxxxxxx-24.43 %
Return on Equity xxxxxxxxxxxxxxx-35.20 %
Return on Total Capital xxxxxxxxxxxxxxx-33.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-13.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx8 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxxxxx4.12

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx3.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx27 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

26/02/2025

1

Buy

$2.70

119.51%

Cyclopharm delivered 2024 revenues up 3% on 2023, including a much stronger 2H24 in which revenues increased by 39% versus the weak prior period result, Bell Potter comments.

Progress is slower than anticipated, the broker highlights, while adding the company has hired additional Business Development personnel to aggressively pursue the multitude of opportunities.

Bell Potter remains confident in management's execution abilities. In 2H24 the installed base increased from 6 devices to 17 with a further 21 scheduled for installation.

The latter numbers compare to signed contracts for 65 devices as at 27 August 2024, hence some 50% of those devices will be installed within weeks, the broker notes.

Cyclopharm has inventory on hand to meet demand and reimbursement is in place with hospitals reporting no issue being paid by Medicare or private payers.

Bell Potter continues to expect the company will be profitable in FY26 and that it has sufficient cash to reach that point. Buy and $2.70 target retained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.60 cents.
Bell Potter forecasts a full year FY26 dividend of 1.00 cents and EPS of 10.20 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CYC STOCK CHART

FNArena News on CYC

1
FNArena Corporate Results Monitor – 26-02-2025

Feb 26 2025 - Australia
2
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View
3
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
4
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
5
Rudi’s View: In Santa We Trust (?)

Dec 05 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps